Head to Head Analysis: Inhibikase Therapeutics (NASDAQ:IKT) & PainReform (NASDAQ:PRFX)

Inhibikase Therapeutics (NASDAQ:IKT) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Inhibikase Therapeutics and PainReform, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	2	4	3	2.90
PainReform	1	0	0	0	1.00

Inhibikase Therapeutics presently has a consensus target price of $4.75, indicating a potential upside of 183.58%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Inhibikase Therapeutics is more favorable than PainReform.

Institutional and Insider Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Inhibikase Therapeutics and PainReform”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26 million	($0.43)	-3.90
PainReform	$31,000.00	22.48	-$5.02 million	($736.66)	-0.00

PainReform has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, PainReform has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Profitability

This table compares Inhibikase Therapeutics and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
PainReform	N/A	N/A	N/A

Summary

PainReform beats Inhibikase Therapeutics on 8 of the 13 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.